- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Research and Markets ( http://www.researchandmarkets.com/reports/c48929 ) has announced the addition of Frost & Sullivan's new report: Diabetes Drug Delivery Methods - Market and Technologies to their offering.
This Frost & Sullivan research service titled Drug Delivery for Diabetes-Market and Technologies provides an overview of advancements in drug delivery technologies in diabetes. It also provides a description of the revenues generated by present insulin delivery methods along with a complete analysis of key market drivers, restraints and trends prevailing in the European market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: insulin syringes, insulin pens, insulin pumps and inhaled insulin.
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Insulin Syringes
- Insulin Pens
- Insulin Pumps
- Inhaled Insulin
The following technologies are covered in this research:
- Inhaled insulin
- Oral insulin
- Transdermal insulin
- Diabetes vaccine
- Gene therapy
Non-invasive Insulin Delivery to Significantly Improve Diabetes Management
The growing demand for non-invasive delivery of insulin, particularly inhaled insulin, is leading to increased focus on the diabetes drug delivery market in Europe. Moreover, due to the irregularity exhibited by a significant number of patients in following insulin therapy, companies are pursuing insulin delivery methods that involve reduced pain, thereby facilitating compliance with the therapy. While various non-invasive delivery methods such as oral insulin, transdermal delivery and nanotechnology are still under research, the overall drug discovery market is anticipated to exhibit strong growth.
For diabetic patients using insulin injections, who are faced with issues such as infections, improper administration of insulin and uncontrolled blood glucose, alternate insulin delivery methods are likely to offer tremendous benefits, remarks the analyst of this research service. In addition, with the ability of inhaled insulin to offer glycaemic control comparable to insulin injections, such advantages are likely to promote market growth.
Competitive Pricing Key to Market Growth
Despite the potential of the market, long-term safety and efficacy of pulmonary delivery of insulin are factors expected to pose a challenge to market growth. While the Food and Drug Administration (FDA) as well as the European Medical Evaluation Agency (EMEA) have approved Exubera (the first inhaled insulin to enter the market), occurrences of pulmonary fibrosis during clinical trials are causing concerns about its safety. Hence, pharmaceutical companies involved in the research of inhaled insulin devices will need to focus on long-term safety of emerging insulin delivery methods.
At the same time, novel insulin delivery methods, such as transdermal insulin delivery, are anticipated to gain prominence across Europe The reimbursement of inhaled insulin, which relies on its cost effectiveness as well as patient compliance, is likely to be hampered by its high prices, says the analyst. Hence, the advantages of convenience, safety and accuracy of inhaled insulin in comparison to conventional insulin, will need to be proved to justify the high costs.
About Research and Markets
We are the leading source for international market research and market data. We hold ‘000’s of major research publications from most of the leading publishers, consultants and analysts. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends
We are a ‘One-Stop-Shop’ for market research reports and industry newsletters from specialist research firms and niche market analysts.
For more information, please click here
Fax: +353 1 4100 980
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015
Seeing quantum motion August 30th, 2015
Artificial leaf harnesses sunlight for efficient fuel production August 30th, 2015